权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Human Umbilical Cord Blood-derived Mononuclear Cell Transplantation Improves Pulmonary Arterial Hypertension in Immunodeficiency Mouse

人脐带血来源的单核细胞移植可改善免疫缺陷小鼠的肺动脉高压

基本信息

批准号：
21390392
负责人：
KITAGWA Tetsuya
金额：
$ 10.9万
依托单位：
The University of Tokushima
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2009
资助国家：
日本
起止时间：
2009 至 2011
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21390392/
关键词：
臍帯血細胞移植未熟肺血管床

项目摘要

Backgrounds and Objectives. The purpose of this study is to investigate whether human umbilical cord blood-derived mononuclear cell(hUCB-MNC) transplantation improves the development of pulmonary arterial hypertension(PAH) in monocrotaline(MCT)-treated mice. HUCB-MNC transplantation may have a new therapeutic potential for several congenital heart defects with primitive pulmonary vasculatures. Methods. MCT-induced PAH model was made using BALB/ c Slc-nu immunodeficiency mouse. HUCB-MNCs were adjusted to 1 x 107/ 0. 25 mL of concentration, and injected intravenously into those mice 4 weeks after MCT administration. The mice were divided into five groups :(1) vehicle-injected mice ;(2) MCT-treated mice ;(3) hUCB-MNC transplantation for PAH mice ;(4) hUCB-MNC+ plasma transplantation for PAH mice ;(5) plasma transplantation for PAH mice. Assessment of PAH were performed by the ratio of right ventricular to ventricular septum plus left ventricular weight(RV/ S+ LV), medial thickness of small pulmonary arteries, and pulmonary acceleration time/ ejection time(PAT/ ET) of the main pulmonary artery by echocardiography. Results. RV/ S+ LV ratio, medial thickness of small pulmonary arteries and PAT/ ET were significantly improved by hUCB-MNC transplantation with or without plasma, respectively. Conclusions. Our data shows that hUCB-MNC transplantation improves MCT-induced PAH and its efficacy is dependent on hUCB-MNCs themselves

背景和目标。本研究的目的是探讨人脐带血来源的单个核细胞（hUCB-MNC）移植是否改善肺动脉高压（PAH）的发展在野百合碱（MCT）处理的小鼠。HUCB-MNC移植可能对几种具有原始肺血管的先天性心脏病具有新的治疗潜力。方法.使用BALB/ c Slc-nu免疫缺陷小鼠制备MCT诱导的PAH模型。将HUCB-MNC调整至1 x 107/ 0。25 mL浓度，并在MCT给药后4周静脉内注射至这些小鼠中。将小鼠分为5组：（1）溶剂注射小鼠;（2）MCT处理小鼠;（3）PAH小鼠的hUCB-MNC移植;（4）PAH小鼠的hUCB-MNC+血浆移植;（5）PAH小鼠的血浆移植。采用超声心动图测量右室与室间隔加左室重量比值（RV/ S+ LV）、肺小动脉中膜厚度、主肺动脉肺动脉加速时间/射血时间（PAT/ ET）等指标评价PAH。结果hUCB-MNC移植后，RV/ S+ LV比值、肺小动脉中膜厚度及PAT/ ET均明显改善。结论.我们的数据显示，hUCB-MNC移植可改善MCT诱导的PAH，其疗效依赖于hUCB-MNC本身